eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
10.33
-0.28 (-2.59%)
Apr 28, 2026, 4:00 PM EDT - Market closed
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
87.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 57.95M |
| Sangamo Therapeutics | 39.55M |
| Pelthos Therapeutics | 16.80M |
| Alterity Therapeutics | 4.43M |
| NeurAxis | 3.57M |
| Rani Therapeutics Holdings | 1.63M |
| Inovio Pharmaceuticals | 65.34K |
EXOZ News
- 18 days ago - eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - Accesswire
- 4 weeks ago - eXoZymes Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - eXoZymes Provides Fourth Quarter and Full Year 2025 Update - Accesswire
- 4 weeks ago - eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 - Accesswire
- 5 weeks ago - Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability - Accesswire
- 6 weeks ago - eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium - Accesswire
- 2 months ago - With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation - Accesswire
- 3 months ago - eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run - Accesswire